Form 4: Longeveron Inc. Executive Joshua Hare Acquires Stock Options

Joshua Hare, Chief Scientific Officer of Longeveron Inc., reports the acquisition of stock options exercisable for 71,254 shares of common stock.

Summary

• Joshua Hare, Chief Scientific Officer of Longeveron Inc., filed a Form 4 on March 6, 2025, reporting a transaction that occurred on March 4, 2025.
• Hare acquired stock options for 71,254 shares of Longeveron Inc. common stock at an exercise price of $1.33 per share.
• The options vest 100% on July 1, 2025, contingent upon stockholder approval at the 2025 Annual Stockholders Meeting to increase the pool of shares available for awards under the Second Amended and Restated 2021 Incentive Award Plan.
• If stockholder approval is not received, the options will not vest until additional shares are added to the plan.
• Following the transaction, Hare directly owns 71,254 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The vesting conditions add a slight positive element as they align with shareholder interests.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting is tied to shareholder approval of the incentive plan, which could encourage management to act in the best interests of shareholders.

Risks

• The vesting of the options is contingent on shareholder approval; if approval is not obtained, the options will not vest until additional shares are added to the plan, potentially delaying the incentive for the executive.
• The value of the options is dependent on the future stock price of Longeveron Inc., which is subject to market risks.

Future Outlook

The vesting of the stock options is contingent upon future stockholder approval at the 2025 Annual Stockholders Meeting.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry to incentivize performance and align management's interests with those of shareholders. The vesting conditions are designed to ensure long-term commitment and value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms.

Stakeholder Impact

• Shareholders: Potential dilution if the options are exercised, but also potential benefit if the options incentivize management to improve company performance.
• Employees: The incentive plan may motivate employees if they are also eligible for stock options or other equity-based compensation.

Next Steps

• Stockholder vote at the 2025 Annual Stockholders Meeting to approve the increase in the share pool for the incentive plan.
• Potential vesting of the stock options on July 1, 2025, if stockholder approval is obtained.

Key Dates